Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) filed an 8-K dated 21-Jul-2025 disclosing two principal items:
- Item 2.02 – Preliminary Q2 2025 results: The company issued a press release (Ex. 99.1) with unaudited second-quarter figures. Numerical details are not included in the filing; the release is incorporated by reference but treated as “furnished,” not “filed,” under the Exchange Act.
- Item 5.02 – Board change: Ownership of Class A shares held by Amneal Group investors fell below a majority threshold, reducing their Board designee rights from six to five under the Stockholders Agreement. Consequently, Amneal Group designee Emily Peterson Alva resigned from the Board and Audit Committee effective 16-Jul-2025. The company states the resignation involved no disagreement with management, the Board, or company policies.
No other material transactions, financial statements, or guidance updates are provided in this report. The filing contains customary Regulation FD and exhibit listings.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) filed an 8-K dated 21-Jul-2025 disclosing two principal items:
- Item 2.02 – Preliminary Q2 2025 results: The company issued a press release (Ex. 99.1) with unaudited second-quarter figures. Numerical details are not included in the filing; the release is incorporated by reference but treated as “furnished,” not “filed,” under the Exchange Act.
- Item 5.02 – Board change: Ownership of Class A shares held by Amneal Group investors fell below a majority threshold, reducing their Board designee rights from six to five under the Stockholders Agreement. Consequently, Amneal Group designee Emily Peterson Alva resigned from the Board and Audit Committee effective 16-Jul-2025. The company states the resignation involved no disagreement with management, the Board, or company policies.
No other material transactions, financial statements, or guidance updates are provided in this report. The filing contains customary Regulation FD and exhibit listings.